Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

ÜNAL, ALİ; Keklik, Muzaffer; MANDACI ŞANLI, NESLİHAN

doi:10.4999/uhod.225936

Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Neslihan MANDACI ŞANLI, (Erciyes Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı ve Kemik İliği Nakli Merkezi, Kayseri, Türkiye)

MUZAFFER KEKLİK, (Erciyes Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı ve Kemik İliği Nakli Merkezi, Kayseri, Türkiye)

Ali ÜNAL (Erciyes Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı ve Kemik İliği Nakli Merkezi, Kayseri, Türkiye)

Uluslararası Hematoloji-Onkoloji Dergisi

2 0

Yıl: 2022 Cilt: 32 Sayı: 1 Sayfa Aralığı: 8 - 15 Metin Dili: İngilizce DOI: 10.4999/uhod.225936 İndeks Tarihi: 02-06-2023

Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Öz:

Inflammatory processes play an important role in the pathophysiology of cGVHD. Serum fibrinogen is a proinflammatory protein with a wide range of functions in inflammation. But its role in GVHD is unclear. The aim of this study was to evaluate the predictive impact of pre-transplantation fibrinogen levels on cGVHD in allo-HSCT recipients. We retrospectively analyzed 249 patients with hematologic diseases undergoing allo-HSCT from 10/10 HLA-matched donors. Serum high fibrinogen levels at the time of HSCT (day 0) were significantly associated with cGVHD development in univariate analyses (OR 2.01, p= 0.012) and multivariate analyses (OR 1.003, p= 0.037). There was no significant association between fibrinogen levels and overall survival, disease-free survival and, acute GVHD (p> 0.05). This is the first report demonstrating the association between high fibrinogen levels and increased cGVHD occurrence.Further studies are warranted and may identify the efficacy of fibrinogen as a predictive marker on cGVHD in allo-HSCT recipients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Markey KA, MacDonald KP, Hill GR. The biology of graft- versus-host disease: experimental systems instructing clinical practice. Blood 124: 354-362, 2014.
2. Holler E. Risk assessment in haematopoietic stem cell trans - plantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 20: 281-294, 2007.
3. Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hemat - opoietic stem cell transplantation. Semin Hematol 49: 10-14, 2012.
4. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiol - ogy. Hematol Oncol Clin North Am 25: 101-116, 2011.
5. Flowers ME, Martin PJ. How we treat chronic graft-versus- host disease. Blood 125: 606-615, 2015.
6. Martin PJ, Counts Jr GW, Appelbaum FR, et al. Life expec- tancy in patients surviving more than 5 years after hematopoi- etic cell transplantation. J Clin Oncol 28:1011-1016, 2010.
7. Liu YC, Chien SH, Fan NW, et al. Prognostic factors on the Graft-versus-Host disease-free and relapse-free survival af - ter adult allogeneic hematopoietic stem cell transplantation. Stem Cells Int 2016: 1-9, 2016.
8. Finke J, Schmoor C, Bethge WA, et al. Prognostic factors affecting outcome after allogeneic transplantation for hema - tological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant 18: 1716- 1726, 2012.
9. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383, 2008.
10. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 373: 1550-1561, 2009.
11. Holler E, Kolb HJ, Greinix H, et al. Bleeding events and mor - tality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant 43: 491-497, 2009.
12. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation be - tween NIH composite skin score, patient reported skin score and outcome: results from the chronic GVHD Consortium. Blood 120: 2545-2552, 2012.
13. Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 17: 167-175, 2011.
14. Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374: 43-53, 2016.
15. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 70: 247- 299, 2005.
16. Adams RA, Passino M, Sachs BD, et al. Fibrin mechanisms and functions in nervous system pathology. Mol Interv 4: 163- 176, 2004.
17. Davalos D, Akassoglou K. Fibrinogen as a key regulator of in- flammation in disease. Semin Immunopathol 34:43-62, 2012.
18. Cooke KR, Luznik L, Sarantopoulus S, et al. The Biology of Chronic Graft-versus- Host disease: A task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials Graft-versus-Host Dis - ease. Biol Blood Marrow Transplant 23: 211-234, 2017.
19. Scheller J, Chalaris A, Schmidt-Arras D, RoseJohn S. The pro- and anti-inflammatory properties of the cytokine interleu- kin-6. Biochim Biophys Acta 1813: 878-888, 2011.
20. Radojcic V, Pletneva MA, Yen H-R, et al. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic scle - rodermatous graft-versus-host disease in a murine model. J Immunol 184: 764-774, 2010.
21. Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127: 2144- 2154, 2016.
22. Armand P, Gibson CJ, Cutler C et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120: 905-913, 2012.
23. Nannya Y, Kataoka K, Hangaishi A, et al. The negative im - pact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int 24:469-476, 2011.
24. Przepiorka D, Weisdorf D, Martin P, et al. Consensus confer- ence on acute GVHD grading. Bone Marrow Transplant 15: 825-828, 1995.
25. Lee SJ, Vogelsang G, Flowers ME. Chronic Graft-Versus- Host disease. Biol Blood Marrow Transplant 9: 215-233, 2003.
26. Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 102: 952-956, 2010.
27. Polterauer S, Grimm C, Seebacher V, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multi - center study. Oncologist 14: 979-985, 2009.
28. Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrin- ogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 109: 1123-1129, 2013.
29. Matsuda S, Takeuchi H, Fukuda K, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postop - erative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus 27: 654-661, 2014.
30. Kinoshita A, Onoda H, Imai N, et al. Elevated plasma fibrino - gen levels are associated with a poor prognosis in patients with hepatocellular carcinoma. Oncology 85: 269-277, 2013.
31. Kim KH, Park TY, Lee JY et al. Prognostic significance of ini - tial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci 29: 507-511, 2014.
32. Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematol Oncol 35: 789-796, 2017.
33. Dai K, Zhang Q, Li Y, et al. Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non- M3 acute myeloid leukemia. Leuk Lymphoma 60:1503-1511, 2019.
34. Niyu JY, Tian T, Zhu HY, et al. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma. Annal He- matol 97:1841-1849, 2018.
35. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Thera - peutic translation for fibrotic disease. Nat Med 18: 1028- 1040, 2012.
36. Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 280: 1336-1345, 2005.
37. Scheller J, Chalaris A, Schmidt-Arras D, RoseJohn S. The pro- and anti-inflammatory properties of the cytokine interleu- kin-6. Biochim Biophys Acta 1813: 878-888, 2011.
38. Nham SU. Characteristics of fibrinogen binding to the domain of CD11c, an alpha subunit of p150,95. Biochem Biophys Res Commun 264: 630-634,1999.
39. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167: 2887-2894, 2001.
40. Hodgkinson CP, Patel K, Ye S. Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thromb Hae- most 100: 301-307, 2008.
41. MacDonald KPA, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus- host disease. The Journal of Clinical In- vestigation 127: 2452-2463, 2017.
42. Verrecchia F, Mauviel A. Transforming growth factor- β and fibrosis. World J. Gastroenterol 13: 3056-3062, 2007.
43. Brüggen MC, Klein I, Greinix H, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft- versus-host disease. Blood 123: 290-299, 2014.
44. Melino M, Gadd VL, Alexander KA, et al. Spatiotemporal characterization of the cellular and molecular contributors to liver fibrosis in a murine hepatotoxic-injury model. Am J Pathol 186: 524-538, 2016.
45. Skogen WF, Senior RM, Griffin GL, Wilner GD. Fibrinogen- derived peptide B beta 1–42 is a multidomained neutrophil chemoattractant. Blood 71: 1475-1479, 1988.
46. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharma - cological intervention? Br. J. Pharmacol. 153: S367-S378, 2009.
47. Ogura S, Nakazato T. The Prognostic Significance of Pre - transplant Plasma Fibrinogen Levels in Autologous Hemat - opoietic Stem Cell Transplantation. Transplant Proc 53: 405- 407, 2021.

APA	MANDACI ŞANLI N, Keklik M, ÜNAL A (2022). Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). , 8 - 15. 10.4999/uhod.225936
Chicago	MANDACI ŞANLI NESLİHAN,Keklik Muzaffer,ÜNAL ALİ Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). (2022): 8 - 15. 10.4999/uhod.225936
MLA	MANDACI ŞANLI NESLİHAN,Keklik Muzaffer,ÜNAL ALİ Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). , 2022, ss.8 - 15. 10.4999/uhod.225936
AMA	MANDACI ŞANLI N,Keklik M,ÜNAL A Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). . 2022; 8 - 15. 10.4999/uhod.225936
Vancouver	MANDACI ŞANLI N,Keklik M,ÜNAL A Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). . 2022; 8 - 15. 10.4999/uhod.225936
IEEE	MANDACI ŞANLI N,Keklik M,ÜNAL A "Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)." , ss.8 - 15, 2022. 10.4999/uhod.225936
ISNAD	MANDACI ŞANLI, NESLİHAN vd. "Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)". (2022), 8-15. https://doi.org/10.4999/uhod.225936

APA	MANDACI ŞANLI N, Keklik M, ÜNAL A (2022). Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Uluslararası Hematoloji-Onkoloji Dergisi, 32(1), 8 - 15. 10.4999/uhod.225936
Chicago	MANDACI ŞANLI NESLİHAN,Keklik Muzaffer,ÜNAL ALİ Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Uluslararası Hematoloji-Onkoloji Dergisi 32, no.1 (2022): 8 - 15. 10.4999/uhod.225936
MLA	MANDACI ŞANLI NESLİHAN,Keklik Muzaffer,ÜNAL ALİ Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Uluslararası Hematoloji-Onkoloji Dergisi, vol.32, no.1, 2022, ss.8 - 15. 10.4999/uhod.225936
AMA	MANDACI ŞANLI N,Keklik M,ÜNAL A Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Uluslararası Hematoloji-Onkoloji Dergisi. 2022; 32(1): 8 - 15. 10.4999/uhod.225936
Vancouver	MANDACI ŞANLI N,Keklik M,ÜNAL A Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Uluslararası Hematoloji-Onkoloji Dergisi. 2022; 32(1): 8 - 15. 10.4999/uhod.225936
IEEE	MANDACI ŞANLI N,Keklik M,ÜNAL A "Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)." Uluslararası Hematoloji-Onkoloji Dergisi, 32, ss.8 - 15, 2022. 10.4999/uhod.225936
ISNAD	MANDACI ŞANLI, NESLİHAN vd. "Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)". Uluslararası Hematoloji-Onkoloji Dergisi 32/1 (2022), 8-15. https://doi.org/10.4999/uhod.225936